Table 2 Gadolinium based contrast agents—elimination pathway, last reported total number of administrations, occurrences of NSF and volume of excess chelate quantity [11]

Omniscan®

(Gadodiamide)

Kidney

438

90

47

25 mmol/L

Optimark®

(Gadoversetamide)

Kidney

7

11

0.8

35 mmol/L

Magnevist®

(Gadopentetate dimeglumine)

Kidney

135

276

95

135 mmol/L

Multihance®

(Gadobenate dimeglumine)

97 % Kidney

3 % Bile

0

8

6

1 mmol/L

Primovist®

(Gadoxetic acid disodium salt)

50 % Bile

50 % Kidney

0

0

0.15

(Not known)

Vasovist®

(Gadofosveset trisodium)

91 % Kidney

9 % Bile

0

0

0.05

(Not known)

Prohance®

(Gadoteridol)

Kidney

1*

2

2.6

1 mmol/L

Gadovist®

(Gadobutrol)

Kidney

1

13

12.3

2 mmo/L

Dotarem®

(Gadoteric acid)

Kidney

1**

11

22.4

0